ReviewBMC infectious diseases2024
Review of the novel antifungal drug olorofim (F901318).
Review in BMC infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Guideline
- From misdiagnosis to precision management: Thoracic vertebral infection caused byMedical mycology case reports · 2026Article
- Central Nervous System Aspergillosis: Advances in Diagnosis, Therapeutics, and Multidisciplinary Management (2026 Update).Mycoses · 2026Review
- In Vitro Evaluation of Olorofim and Amphotericin B Combination Therapy AgainstJournal of fungi (Basel, Switzerland) · 2026Article
- Invasive Fungal Sinusitis in Patients With Hematological Malignancies: A 20-Year Study From a Tertiary Academic US Hospital System.Open forum infectious diseases · 2026Article
- Drug-Induced Liver Injury From a Novel Antifungal - Olorofim.ACG case reports journal · 2026Article
- Identification of GPI-Anchored Wall Transfer Protein 1 Modulators for Fungal Infections Through Generative AI and Physics-Based Approaches.International journal of molecular sciences · 2026Article
- Article
- The dual role of azoles: lifesaving antifungals and drivers of resistance - a One Health perspective.Nature communications · 2026Review
- Current and emerging therapies for fungal biofilms and systemic infections.Critical reviews in microbiology · 2026Review
- Molecular mechanisms drivingFrontiers in molecular biosciences · 2026Review
- A quiet but growing threat: Global perspectives on antifungal resistance and future therapeutic approaches.Indian journal of pharmacology · 2026Review
- Pathogenesis and Triazole Resistance inInfection and drug resistance · 2026Review
- Cerebral Aspergillosis: Diagnostic Challenges, Therapeutic Strategies, and Future Research.CNS drugs · 2026Review
- Invasive Pulmonary Aspergillosis in Non-Neutropenic Patients: An Evolving Clinical Paradigm.Diagnostics (Basel, Switzerland) · 2025Review
- When Should Clinical Mycology Laboratories Perform Antifungal Susceptibility Testing? Revisiting Practice Through the Lens of Intrinsic Resistance.Mycopathologia · 2025Review
- StudyingPharmaceuticals (Basel, Switzerland) · 2025Review
- Antagonistic interaction between posaconazole and olorofim in a murine model of invasive pulmonary aspergillosis.The Journal of antimicrobial chemotherapy · 2025Article
- Coccidioidomycosis-Attributable Death in the United States: An Analysis of Cases Reported on Death Certificates, 2018-2023.Journal of fungi (Basel, Switzerland) · 2025Article
- Azole-ResistantJournal of fungi (Basel, Switzerland) · 2025Review
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is clearly a need for novel antifungal agents, not only concerning spectrum, but also oral bioavailability, tolerability, and drug-drug interactions. There is growing concern for antifungal resistance for current available antifungals, mainly driven by environmental fungicide use or long-term exposure to antifungals, in the setting of mould-active prophylaxis or for chronic antifungal infections, such as chronic pulmonary aspergillosis. Moreover, the incidence of breakthrough infections is increasing, because of the introduction of (mould-active) prophylaxis (1-4). There is emergence of difficult to treat invasive fungal infections, such as those caused by Lomentospora prolificans, cryptic species of Aspergillus, Scedosporium and Coccidioides. Olorofim (F901318) is the first-in class of the orotomides, a novel antifungal class targeting dihydroorotate dehydrogenase (DHODH), a key enzyme in the biosynthesis of pyrimidines. Olorofim shows good in vitro and in vivo activity against Aspergillus species, rare and difficult to treat moulds and endemic dimorphic fungi, including azole- and amphotericin-resistant isolates. It lacks activity against yeasts and the Mucorales species. It is only orally available and shows very promising results in ongoing clinical trials. In this review we will describe the mechanism of action of olorofim, the spectrum of activity in vitro and in vivo, pharmacokinetics, pharmacodynamics, drug-drug interactions, resistance, and clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.